Lancora · DIN 02459981 · 7.5 mg · tablet
Limited Use, Reason for Use code 538 requiredMarketed · checked November 19, 2026
StatusLimited Use, Reason for Use code 538 required
Write on scriptReason for Use code 538 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 538
Reason for Use code 538
For the treatment of stable chronic heart failure with reduced left ventricular ejection fraction (LVEF) (less than or equal to 35%) in adult patients with New York Heart Association (NYHA) classes II or III who are in sinus rhythm with a resting heart rate greater than or equal to 77 beats per minute (bpm), to reduce the incidence of cardiovascular mortality and hospitalizations for worsening heart failure, administered in combination with standard chronic heart failure therapies if the following are met:
- Patients with NYHA class II to III symptoms despite at least four weeks of treatment with a stable dose of an angiotensin converting enzyme inhibitor (ACEI) or an angiotensin II receptor blocker (ARB) in combination with a beta blocker and, if tolerated, a mineralocorticoid receptor antagonist (MRA); AND
- Patients with at least one hospitalization due to heart failure in the last year; AND
- Resting heart rate must be documented as greater than or equal to 77 bpm on average using either an ECG on at least three separate visits or by continuous monitoring.
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Lancora · DIN 02459981
Manufacturer: Servier Canada Inc.; listing date 2018-10-31
Health Canada: Marketed since 2017-03-17 · brand LANCORA · ATC C01EB17 IVABRADINE · form Tablet · route Oral · ingredients IVABRADINE (IVABRADINE HYDROCHLORIDE) 7.5 MG · company Servier canada inc · schedule Prescription
Lancora: Formulary list price $1.70 per unit (the source does not state the unit; exact figure $1.7032). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02459981)
Source record
DIN 02459981: Lancora
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240400175; group id 283; item number 0604; lccId 00311; manufacturer id SEV
Source form: Tab; strength: 7.5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.7032; ministry $1.7032
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02459981
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94729
Shortage status: not checked (no credentials)